Tech Company Financing Transactions

BioLamina Funding Round

Lauxera Capital Partners, Bure and Northislet participated in a $18.1 million capital raise for BioLamina. The financing round was recorded on 9/12/2023.

Transaction Overview

Company Name
Announced On
9/12/2023
Transaction Type
Venture Equity
Amount
$18,140,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to expand operations and its R&D sector.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
BioLamina AB Löfströms Allé 5
Sundbyberg, 172 66
SE
Phone
Undisclosed
Email Address
Overview
BioLamina is a biotechnology company built on a scientific foundation with a legacy in matrix biology and cell culture-based research. We want to help scientists who have struggled for decades to culture embryonic stem cells, induced pluripotent stem cells, and other primary cells. By providing tools for efficient and easy culture, BioLamina aims to smooth the path towards safe and effective cell therapy. Whether your goal is to answer basic scientific questions, advance cell therapies, or make models for drug development, our products can help you in your journey. The power of our Biolaminin® substrates has been shown in numerous publications and they will continue to provide vital support for the stem cell community -- from scientific concepts to clinical studies.
Profile
BioLamina LinkedIn Company Profile
Social Media
BioLamina Company Twitter Account
Company News
BioLamina News
Facebook
BioLamina on Facebook
YouTube
BioLamina on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Veronica Sköld
  Veronica Sköld LinkedIn Profile  Veronica Sköld Twitter Account  Veronica Sköld News  Veronica Sköld on Facebook
Chief Financial Officer
Magnus Åkerhielm
  Magnus Åkerhielm LinkedIn Profile  Magnus Åkerhielm Twitter Account  Magnus Åkerhielm News  Magnus Åkerhielm on Facebook
Chief Operating Officer
Ulrika Ljungkvist
  Ulrika Ljungkvist LinkedIn Profile  Ulrika Ljungkvist Twitter Account  Ulrika Ljungkvist News  Ulrika Ljungkvist on Facebook
Chief Scientific Officer
Therése Kallur
  Therése Kallur LinkedIn Profile  Therése Kallur Twitter Account  Therése Kallur News  Therése Kallur on Facebook


 

 

Browse more venture capital transactions:

Prev: 9/12/2023: CertifID venture capital transaction
Next: 9/12/2023: Sparta Biomedical venture capital transaction

 

Share this article

 


About Our Venture Capital Transactions Database

We do our best to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary